Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could half a dose be enough? new study tests lighter blood thinner after stents

NCT ID NCT07622056

Disease control Sponsor: Kaohsiung Veterans General Hospital. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 15, 2026 · Updated 2 times

Summary

This study tested whether a half-dose blood thinner (ticagrelor) taken alone after heart stent placement works as well as the standard two-drug therapy in East-Asian patients with chronic coronary syndrome. Sixty participants were randomly assigned to one of three treatment groups. The main goal was to measure how well the drugs prevented blood clots, while also watching for bleeding risks. Results may help tailor safer, simpler treatment for this population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

54 people

The number who actually took part.

Started

Jan 2024

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * adults with CCS, defined per the 2019 ESC criteria, scheduled for elective PCI on the day after admission * able to provide consent Exclusion Criteria: * ACS at presentation * Prior intolerance to any study drug * Active bleeding or BARC ≥ 3 bleeding within three months, * NYHA IV heart failure * Platelet count below 100 × 10⁹/L * eGFR below 30 mL/min/1.73 m² * Severe hepatic dysfunction * Planned non-cardiac surgery within twelve months * Patient who inabley to provide consent. * Patients in whom PCI was not performed at the index procedure (per protocol)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic coronary syndrome; coronary artery disease; percutaneous coronary intervention are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder Coronary Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic coronary syndrome; coronary artery disease; percutaneous coronary intervention Coronary heart disease

Contacts and locations

Locations

  • Kaohsiung Veterans General Hospital

    Kaohsiung City, 813414, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.